The ROCplot online tool was used to evaluate whether higher transcriptional levels of UBE2T, UBE2C, and BIRC5, could qualify as putative biomarkers of response to (neo)adjuvant therapy in BC [26]. This evidence concerns the gene BIRC5 and breast cancer.